Open Payments

ASCENSION ST JOHN HOSPITAL

Type
Teaching hospital
Where
Detroit, MI
Medicare CCN
230165
Received
$1,066,958 in 225 records, 2023 ($30,000 general, $1,036,958 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment8$30,000
2023Research payment217$1,036,958

By company

CompanyRecordsAmountYears
PFIZER INC.72$742,5602023
Medtronic, Inc.61$94,2622023
Genentech, Inc.17$44,1182023
Eli Lilly and Company3$38,3862023
Saranas, Inc.22$31,4612023
Penumbra, Inc.14$25,8822023
InspireMD Ltd1$16,7162023
Amgen Inc.1$14,0002023
AngioDynamics, Inc.1$13,0002023
Gilead Sciences, Inc.8$12,8622023
Endologix LLC7$9,4252023
ERBE USA Inc2$7,0002023
Impulse Dynamics (USA) Inc.2$4,8222023
Celgene Corporation1$3,0002023
Genetesis, Inc.4$2,4002023
Takeda Pharmaceuticals U.S.A., Inc.1$2,0002023
ABBVIE INC.1$2,0002023
Wilson Cook Medical Incorporated1$2,0002023
Pharmacyclics LLC, an AbbVie Company4$6322023
Biogen, Inc.1$3802023
Abbott Laboratories1$502023

By nature of payment

NatureRecordsAmount
Research payment217$1,036,958
Long term medical supply or device loan1$13,000
Space rental or facility fees (teaching hospital only)4$8,000
Honoraria1$5,000
Education2$4,000

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-31AngioDynamics, Inc.$13,000Long term medical supply or device loanIn-kind items and servicesSolero Device, Oncology2023
2023-12-29PFIZER INC.$7,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-12-29Penumbra, Inc.$3,737Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-12-27Endologix LLC$1,950Research paymentCash or cash equivalentENDOCROSS Device Device, Cardiology/Vascular DiseasesDetour II Study2023
2023-12-22PFIZER INC.$8,141Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-12-22PFIZER INC.$4,440Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-12-14PFIZER INC.$19,108Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-12-08PFIZER INC.$13,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO2023
2023-12-07PFIZER INC.$20,298Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-12-07PFIZER INC.$8,195Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-12-04InspireMD Ltd$16,716Research paymentCash or cash equivalentCGuard Device, CardiologySafety and Efficacy of the CGuard Carotid Stent System in Carotid Artery Stenting2023
2023-11-29Endologix LLC$1,105Research paymentCash or cash equivalentNellix 3.5 Confirm Study2023
2023-11-25PFIZER INC.$28,959Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-11-25PFIZER INC.$8,255Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-11-21Medtronic, Inc.$1,250Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-11-21Medtronic, Inc.$1,250Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-11-21Medtronic, Inc.$1,200Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-11-21Medtronic, Inc.$1,200Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-11-20Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-11-20Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-11-20Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-11-20Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-11-15Medtronic, Inc.$11,081Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-11-15Penumbra, Inc.$2,948Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-11-09Impulse Dynamics (USA) Inc.$3,822Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DeviceAssessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)2023
2023-11-04PFIZER INC.$25,722Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-11-04PFIZER INC.$1,919Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-11-03Saranas, Inc.$1,750Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-10-27Saranas, Inc.$2,500Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-10-27Genentech, Inc.$1,000Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-10-26Medtronic, Inc.$1,375Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-10-26Medtronic, Inc.$1,375Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-10-26Medtronic, Inc.$735Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-10-26Medtronic, Inc.$735Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-10-26Medtronic, Inc.$7Research paymentIn-kind items and servicesSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2023
2023-10-25PFIZER INC.$8,000Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF2023
2023-10-24PFIZER INC.$3,456Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-10-23Penumbra, Inc.$3,500Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-10-18Medtronic, Inc.$875Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2023
2023-10-18Medtronic, Inc.$875Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2023
2023-10-18PFIZER INC.$700Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-10-18Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2023
2023-10-18Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2023
2023-10-16Medtronic, Inc.$1,960Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2023
2023-10-16Medtronic, Inc.$1,960Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2023
2023-10-13Penumbra, Inc.$848Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-10-11PFIZER INC.$6,234Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-10-11PFIZER INC.$3,023Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-10-03Penumbra, Inc.$1,000Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-09-23PFIZER INC.$53,806Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-09-23PFIZER INC.$543Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-09-20Eli Lilly and Company$4,000Research paymentCash or cash equivalentA PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIEN2023
2023-09-19Penumbra, Inc.$1,869Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-09-18Saranas, Inc.$3,250Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-09-12Medtronic, Inc.$1,968Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-09-12Medtronic, Inc.$1,968Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-09-06Saranas, Inc.$2,000Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-09-06Endologix LLC$1,950Research paymentCash or cash equivalentENDOCROSS Device Device, Cardiology/Vascular DiseasesDetour II Study2023
2023-09-06Impulse Dynamics (USA) Inc.$1,000Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2023
2023-09-05Genetesis, Inc.$1,750Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMICRO2023
2023-09-02PFIZER INC.$35,013Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-09-02PFIZER INC.$1,919Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-08-31Medtronic, Inc.$5Research paymentIn-kind items and servicesSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2023
2023-08-24PFIZER INC.$25,949Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-08-24PFIZER INC.$3,295Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-08-23Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-08-23Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-08-18Saranas, Inc.$2,208Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-08-18Saranas, Inc.$1,173Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-08-18Saranas, Inc.$525Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-08-17PFIZER INC.$154Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-08-15Medtronic, Inc.$1,728Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-08-15Medtronic, Inc.$1,728Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-08-15Penumbra, Inc.$1,551Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-08-14Medtronic, Inc.$1,375Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-08-14Medtronic, Inc.$1,375Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-08-09Eli Lilly and Company$33,065Research paymentCash or cash equivalentSTUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE2023
2023-08-08PFIZER INC.$18,881Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-08-08PFIZER INC.$3,023Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-08-03Penumbra, Inc.$2,000Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-08-02Genentech, Inc.$1,895Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-07-26PFIZER INC.$46,618Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-07-26PFIZER INC.$6,725Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-07-26PFIZER INC.$703Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-07-19Gilead Sciences, Inc.$1,040Research paymentCash or cash equivalentSunlenca Drug, HIVA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2023
2023-07-18Penumbra, Inc.$138Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-07-13PFIZER INC.$5,143Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-07-13Medtronic, Inc.$400Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2023
2023-07-13Medtronic, Inc.$400Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2023
2023-07-11PFIZER INC.$13,336Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-07-11PFIZER INC.$3,295Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-07-06PFIZER INC.$10,146Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-07-06PFIZER INC.$1,040Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-07-06Medtronic, Inc.$228Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-07-06Medtronic, Inc.$228Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-06-29PFIZER INC.$2,213Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-28Genentech, Inc.$7,353Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-06-28PFIZER INC.$6,303Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-06-26Genentech, Inc.$2,000Research paymentCash or cash equivalentTNKase Biological, Metabolism & Primary CareTenecteplase in stroke patients between 4 5 and 24 hours2023
2023-06-26Genentech, Inc.$800Research paymentCash or cash equivalentTNKase Biological, Metabolism & Primary CareTenecteplase in stroke patients between 4 5 and 24 hours2023
2023-06-26Genentech, Inc.$800Research paymentCash or cash equivalentTNKase Biological, Metabolism & Primary CareTenecteplase in stroke patients between 4 5 and 24 hours2023
2023-06-26Genentech, Inc.$40Research paymentCash or cash equivalentTNKase Biological, Metabolism & Primary CareTenecteplase in stroke patients between 4 5 and 24 hours2023
2023-06-24PFIZER INC.$3,966Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-06-24PFIZER INC.$3,667Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-06-22PFIZER INC.$463Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-21Gilead Sciences, Inc.$833Research paymentCash or cash equivalentSunlenca Drug, HIVA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2023
2023-06-21Medtronic, Inc.$55Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-06-21Medtronic, Inc.$55Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-06-16PFIZER INC.$27,693Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-16Genentech, Inc.$3,924Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-06-14PFIZER INC.$772Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-08PFIZER INC.$25,215Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-06-08Penumbra, Inc.$248Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-06-03PFIZER INC.$3,091Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-03PFIZER INC.$271Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-06-01Pharmacyclics LLC, an AbbVie Company$158Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2023
2023-06-01Pharmacyclics LLC, an AbbVie Company$158Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2023
2023-06-01Pharmacyclics LLC, an AbbVie Company$158Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2023
2023-06-01Pharmacyclics LLC, an AbbVie Company$158Research paymentCash or cash equivalentIMBRUVICA Drug, ONCOLOGYinformCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)2023
2023-05-31Genetesis, Inc.$250Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMICRO2023
2023-05-26PFIZER INC.$18,911Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-05-25PFIZER INC.$25,835Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-05-25PFIZER INC.$2,851Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-05-25Saranas, Inc.$2,308Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-05-25Saranas, Inc.$150Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-05-16PFIZER INC.$4,719Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-05-15Penumbra, Inc.$801Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-05-12Medtronic, Inc.$2,253Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-05-12Medtronic, Inc.$2,253Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-05-12Medtronic, Inc.$1,448Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-05-12Medtronic, Inc.$1,448Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-05-11Medtronic, Inc.$6,250Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-05-11Medtronic, Inc.$6,250Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-05-10Genentech, Inc.$2,819Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-05-10PFIZER INC.$1,854Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-05-10Genentech, Inc.$1,293Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-05-10Abbott Laboratories$50Research paymentCash or cash equivalentAVEIR Device, Cardiac Rhythm ManagementThe LEADLESS II IDE Study for the Nanostim Leadless Pacemaker2023
2023-05-09PFIZER INC.$2,936Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-05-09Medtronic, Inc.$423Research paymentIn-kind items and servicesSYMPLICITY G3 Device, Renal Denervation SystemSPYRAL AFFIRM2023
2023-05-06PFIZER INC.$2,751Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-05-03Celgene Corporation$3,000Research paymentCash or cash equivalentRevlimid Drug, HematologyConnect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A2023
2023-05-03Saranas, Inc.$1,300Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-05-03Saranas, Inc.$1,173Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-05-03Saranas, Inc.$1,035Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-05-03Saranas, Inc.$750Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-05-03Saranas, Inc.$100Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-04-29ERBE USA Inc$5,000HonorariaCash or cash equivalent2023
2023-04-27PFIZER INC.$18,236Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-04-27Medtronic, Inc.$6,858Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-04-27Medtronic, Inc.$6,858Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-04-27Saranas, Inc.$3,708Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-04-24Medtronic, Inc.$2,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-04-24Medtronic, Inc.$2,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2023
2023-04-24Genetesis, Inc.$325Research paymentCash or cash equivalentCardioFlux Device, Cardiovascular DiagnosticMICRO2023
2023-04-22PFIZER INC.$12,500Research paymentCash or cash equivalentA PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI2023
2023-04-21PFIZER INC.$38,764Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-04-20Penumbra, Inc.$945Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2023
2023-04-19Takeda Pharmaceuticals U.S.A., Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2023
2023-04-19Gilead Sciences, Inc.$833Research paymentCash or cash equivalentSunlenca Drug, HIVA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2023
2023-04-13Medtronic, Inc.$1,507Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2023
2023-04-13Medtronic, Inc.$1,507Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2023
2023-04-12PFIZER INC.$6,000Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-04-12PFIZER INC.$2,510Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-04-09ERBE USA Inc$2,000EducationCash or cash equivalent2023
2023-04-07Genentech, Inc.$4,242Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-04-07Genentech, Inc.$2,819Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-04-07Genentech, Inc.$1,769Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-30Endologix LLC$1,105Research paymentCash or cash equivalentNellix 3.5 Confirm Study2023
2023-03-30Endologix LLC$1,105Research paymentCash or cash equivalentNellix 3.5 Confirm Study2023
2023-03-30Endologix LLC$1,105Research paymentCash or cash equivalentNellix 3.5 Confirm Study2023
2023-03-30Endologix LLC$1,105Research paymentCash or cash equivalentNellix 3.5 Confirm Study2023
2023-03-29Gilead Sciences, Inc.$3,840Research paymentCash or cash equivalentSunlenca Drug, HIVA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2023
2023-03-29Genentech, Inc.$2,040Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-29Genentech, Inc.$1,769Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-24PFIZER INC.$1,268Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-03-23PFIZER INC.$2,210Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-03-21Gilead Sciences, Inc.$2,593Research paymentCash or cash equivalentSunlenca Drug, HIVA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2023
2023-03-18PFIZER INC.$154Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-03-15Genentech, Inc.$4,242Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-09PFIZER INC.$13,788Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-03-09Saranas, Inc.$2,000Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2023
2023-03-07PFIZER INC.$24,381Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-03-01PFIZER INC.$4,329Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-03-01Gilead Sciences, Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2023
2023-02-28PFIZER INC.$9,582Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-02-24Amgen Inc.$14,000Research paymentCash or cash equivalentP0 ASCVD Olpasiran Prescreening for CVOT2023
2023-02-22Gilead Sciences, Inc.$683Research paymentCash or cash equivalentSunlenca Drug, HIVA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2023
2023-02-21Penumbra, Inc.$2,000EducationCash or cash equivalent2023
2023-02-21Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-02-21Medtronic, Inc.$1,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-02-21Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-02-21Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-02-21Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-02-21Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2023
2023-02-18PFIZER INC.$3,372Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-02-16Medtronic, Inc.$300Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-02-16Medtronic, Inc.$300Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-02-15PFIZER INC.$2,144Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-02-11Medtronic, Inc.$1,395Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2023
2023-02-10ABBVIE INC.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentLINZESS Drug, GASTROENTEROLOGY2023

The latest 200 records of 225.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDetroit city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Detroit, MI
County
Wayne County, MI
State
Michigan
Population B01003638,5301,772,25910,077,761
Population, 2020 census P1639,1111,793,56110,077,331
Median age B0100235.237.940.2
Under 18 B0100124.8%23.6%21.2%
65 and over B0100115.1%16.6%18.6%
Households B11001257,998700,5914,076,369
Foreign born B050026.6%10.3%7.2%
Median household income B19013$39,938$60,539$72,875
Median family income B19113$49,398$79,522$93,357
Per capita income B19301$24,594$34,906$40,735
Poverty rate B1700132.7%20.8%13.2%
Unemployment rate B2302514.0%8.7%5.7%
Civilian labor force B23025268,955828,8385,018,449
Mean commute (minutes) B0801324.824.724.2
Bachelor's degree or higher B1500318.1%27.6%32.4%
Housing units B25001329,393801,0834,622,236
Owner-occupied B2500350.3%64.8%73.2%
Renters B2500349.7%35.2%26.8%
Median home value B25077$83,900$178,500$231,600
Median gross rent B25064$1,074$1,132$1,129
White, not Hispanic B0300210.8%47.9%72.4%
Black B0300275.0%36.6%13.1%
Hispanic or Latino B030028.3%6.9%5.9%
Asian B030021.7%3.7%3.4%
American Indian and Alaska Native B030020.2%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.